AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking
- PMID: 24791904
- PMCID: PMC4067562
- DOI: 10.1016/j.ajhg.2014.04.005
AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking
Abstract
Adaptor protein complex 1 (AP-1) is an evolutionary conserved heterotetramer that promotes vesicular trafficking between the trans-Golgi network and the endosomes. The knockout of most murine AP-1 complex subunits is embryonically lethal, so the identification of human disease-associated alleles has the unique potential to deliver insights into gene function. Here, we report two founder mutations (c.11T>G [p.Phe4Cys] and c.97C>T [p.Arg33Trp]) in AP1S3, the gene encoding AP-1 complex subunit σ1C, in 15 unrelated individuals with a severe autoinflammatory skin disorder known as pustular psoriasis. Because the variants are predicted to destabilize the 3D structure of the AP-1 complex, we generated AP1S3-knockdown cell lines to investigate the consequences of AP-1 deficiency in skin keratinocytes. We found that AP1S3 silencing disrupted the endosomal translocation of the innate pattern-recognition receptor TLR-3 (Toll-like receptor 3) and resulted in a marked inhibition of downstream signaling. These findings identify pustular psoriasis as an autoinflammatory phenotype caused by defects in vesicular trafficking and demonstrate a requirement of AP-1 for Toll-like receptor homeostasis.
Copyright © 2014 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
Figures



References
-
- Robinson M.S. Adaptable adaptors for coated vesicles. Trends Cell Biol. 2004;14:167–174. - PubMed
-
- Griffiths C.E.M., Barker J.N. Psoriasis. In: Burns T., Breathnach S., Cox N., Griffiths C., editors. Rook’s Textbook of Dermatology. Wiley-Blackwell; Chichester: 2010. 20.21–20.60.
-
- Marrakchi S., Guigue P., Renshaw B.R., Puel A., Pei X.Y., Fraitag S., Zribi J., Bal E., Cluzeau C., Chrabieh M. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 2011;365:620–628. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- RC2 HL102926/HL/NHLBI NIH HHS/United States
- DH_/Department of Health/United Kingdom
- MR/L01257X/1/MRC_/Medical Research Council/United Kingdom
- HL-102924/HL/NHLBI NIH HHS/United States
- RC2 HL102924/HL/NHLBI NIH HHS/United States
- HL-102926/HL/NHLBI NIH HHS/United States
- HL-102925/HL/NHLBI NIH HHS/United States
- HL-102923/HL/NHLBI NIH HHS/United States
- RC2 HL102923/HL/NHLBI NIH HHS/United States
- UC2 HL102926/HL/NHLBI NIH HHS/United States
- UC2 HL103010/HL/NHLBI NIH HHS/United States
- HL-103010/HL/NHLBI NIH HHS/United States
- UC2 HL102923/HL/NHLBI NIH HHS/United States
- UC2 HL102924/HL/NHLBI NIH HHS/United States
- RC2 HL103010/HL/NHLBI NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- RC2 HL102925/HL/NHLBI NIH HHS/United States
- UC2 HL102925/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials